GlaxoSmithKline: Melanoma trials
The registry lists 29 Melanoma studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 17 have results posted.
Phase 1 13Phase 2 13Phase 3 4No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid TumorsCompletedNCT03693612Phase 1/2Results posted
- An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's LymphomaCompletedNCT02783300Phase 1Results posted
- Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or TrametinibTerminatedNCT02314143Phase 2Results posted
- Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and MetabolitesTerminatedNCT01978236Phase 2Results posted
- Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)CompletedNCT01928940Phase 2Results posted
- A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the BrainCompletedNCT01266967Phase 2Results posted
- GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive MelanomaCompletedNCT01245062Phase 3Results posted
- A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) MelanomaCompletedNCT01227889Phase 3Results posted
- Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous MelanomaCompletedNCT01213472Phase 1Results posted
- A Study of GSK2118436 in BRAF Mutant Metastatic MelanomaCompletedNCT01153763Phase 2Results posted
- Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin CancerCompletedNCT01149343Phase 1Results posted
- Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF InhibitorCompletedNCT01037127Phase 2Results posted
- A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced MelanomaCompletedNCT00942162Phase 2Results posted
- Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous MelanomaCompletedNCT00896480Phase 2Results posted
- A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma PatientsTerminatedNCT00849875Phase 2Results posted
- A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their TumorTerminatedNCT00796445Phase 3Results posted
- MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous MelanomaTerminatedNCT00706238Phase 2Results posted
- A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With CancerActive, not recruitingNCT06521567Phase 1/2
- A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)Active, not recruitingNCT02817633Phase 1
- Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With MelanomaWithdrawnNCT02447939Phase 1
- Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous MelanomaNo longer availableNCT02416232
- Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and MidazolamCompletedNCT02082665Phase 1
- A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid TumorsCompletedNCT02065063Phase 1
- A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive TumorsCompletedNCT01954043Phase 1
- Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable MelanomaCompletedNCT01767454Phase 1
- A Study of PNT2258 in Patients With Advanced Solid TumorsCompletedNCT01191775Phase 1
- Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or LymphomaCompletedNCT00687622Phase 1
- Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic MelanomaCompletedNCT00107718Phase 2
- Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic MelanomaStatus unknownNCT00002767Phase 3